TEVA MNTA – That may be another benefit of the new formulation, but I think Teva is more concerned about a generic Copaxone in the US than they are about competition from the new oral meds.
Let me put this another way: If not for the threat of a generic, I doubt that Teva would've embarked on the program to develop a low-volume formulation.
Addendum re the low-volume formulation of Copaxone: Teva declined to comment on whether the new formulation has a narrower needle than the standard formulation. I guess is that it does not; to my knowledge, needle size has never been a consequential issue for Copaxone uptake.
Market Data 
Markets 
AI
